Cerus (CERS) Q3 2024 earnings summary

Executive summary

• Q3 2024 product revenue rose 16% year-over-year to $46 million, driven by strong North American platelet business and growing INTERCEPT Fibrinogen Complex (IFC) adoption in the U.S.

• Net loss narrowed to $2.9 million ($0.02 per share) from $7.3 million in Q3 2023, with positive non-GAAP adjusted EBITDA of $4.4 million.

• Raised full-year 2024 product revenue guidance to $177–$179 million and IFC revenue guidance to $9–$10 million.

• Secured a new BARDA contract for INTERCEPT RBCs and advanced regulatory submissions for the LED Illuminator in Europe.

• Pathogen inactivation technology adoption is expanding in the U.S. and internationally, supported by positive clinical trial data and regulatory momentum.

Financial highlights

• Q3 2024 product revenue reached $46 million, up 16% year-over-year; total Q3 revenue was $50.7 million, up 7%; nine-month product revenue totaled $129.5 million, up 18%.

• U.S. product revenues grew 17% year-over-year; North America Q3 product revenue was $31.5 million, up 21%.

• Product gross profit was $26.2 million, up 20% year-over-year; gross margin improved to 56.9%.

• Operating expenses were $31.8 million, down 8% year-over-year, with R&D expenses decreasing 17%.

• Cash and short-term investments at quarter-end were $75.6 million; working capital increased to $87 million.

Outlook and guidance

• Full-year 2024 product revenue guidance raised to $177–$179 million; IFC revenue guidance increased to $9–$10 million.

• Expects stable gross margins and continued leverage from operating expenses for the remainder of 2024.

• Targeting non-GAAP adjusted EBITDA breakeven for full-year 2024.

• Government contract revenue expected to increase in 2025 as new BARDA contract activities ramp up.

• Management believes available liquidity is sufficient for at least the next 12 months.